AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22388466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (35 mg/d)
Number of subjects: 16
Study 22388466 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (32.14 mg/d)
Number of subjects: 16
Study 20167436 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase quitters with higher levels of Anger
Number of subjects: 202
Study 20167436 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase quitters with higher levels of Craving
Number of subjects: 202
Study 20167436 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase quitters
Number of subjects: 202
Study 20167436 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall withdrawal symptoms (regardless of quit phase)
Number of subjects: 202
Study 18206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Less computationally complex physical identity task
Number of subjects: 0
Study 18206285 — intervention group
Group type: EXPERIMENTAL
Intervention: More complex adding task
Number of subjects: 0
Study 18206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked condition
Number of subjects: 0
Study 18206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed condition
Number of subjects: 0
Study 15775946 — intervention group
Group type: EXPERIMENTAL
Intervention: Deciduous molar anchorage
Number of subjects: 30
Study 15775946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed deciduous molar and premolar anchorage
Number of subjects: 30
Study 15775946 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolar anchorage
Number of subjects: 30
Study 12519461 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg haloxazolam (HAX)
Number of subjects: 17
Study 12519461 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg flunitrazepam (FNZ)
Number of subjects: 17
Study 12519461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam (TRI)
Number of subjects: 17
Study 10653869 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood cell transplantation (BCT)
Number of subjects: 111
Study 10653869 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 111
Study 8678464 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine in active ulcerative colitis
Number of subjects: 0
Study 8678464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8678464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus layer thickness measurements
Number of subjects: 0
Study 1847796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin, 1 g every 6 hours for 5 days
Number of subjects: 40
Study 1847796 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 40
Study 6339024 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC and BCG
Number of subjects: 94
Study 6339024 — intervention group
Group type: COMPARATOR
Intervention: Careful observation
Number of subjects: 94
Study 31269780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate-intensity treadmill exercise (15 min)
Number of subjects: 40
Study 31269780 — intervention group
Group type: COMPARATOR
Intervention: Seated task (control)
Number of subjects: 40
Study 28213188 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH+RISP (1mg/kg/d+0.5mg/d)
Number of subjects: 84
Study 28213188 — intervention group
Group type: COMPARATOR
Intervention: MPH+PLCO (1mg/kg/d+placebo)
Number of subjects: 84
Study 26426270 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming at 12 months and placebo at 18 months
Number of subjects: 1760
Study 26426270 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo at 12 months and deworming at 18 months
Number of subjects: 1760
Study 26426270 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming at both 12 and 18 months
Number of subjects: 1760
Study 26426270 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both 12 and 18 months
Number of subjects: 1760
Study 23960104 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication intervention (PCI)
Number of subjects: 19
Study 23960104 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded task intervention (GTI)
Number of subjects: 19
Study 23960104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 21778332 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow skin cooling (≈2°C/h)
Number of subjects: 11
Study 21778332 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium skin cooling (≈4°C/h)
Number of subjects: 11
Study 21778332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast skin cooling (≈6°C/h)
Number of subjects: 11
Study 18639221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bascom's simple surgery
Number of subjects: 55
Study 18639221 — intervention group
Group type: COMPARATOR
Intervention: Cleft closure
Number of subjects: 55
Study 17990451 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie Capsule (QXC)
Number of subjects: 44
Study 17990451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 44
Study 15069559 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert pianists
Number of subjects: 2
Study 15069559 — intervention group
Group type: COMPARATOR
Intervention: Non-musicians
Number of subjects: 2
Study 12150227 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-contingent consequences with positive mood
Number of subjects: 0
Study 12150227 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent consequences
Number of subjects: 0
Study 10456306 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale ultrasonography
Number of subjects: 45
Study 10456306 — intervention group
Group type: EXPERIMENTAL
Intervention: Color and pulsed Doppler ultrasonography
Number of subjects: 45
Study 7761738 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed exposure to bright light (4‐7,000 lux between 2400 and 0400 hours on each of three night shifts)
Number of subjects: 0
Study 7761738 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (2 mg at 0800 hours, then 1 mg at 1100 and 1400 hours)
Number of subjects: 0
Study 7761738 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (dim red light at less than 50 lux or placebo sucrose capsules)
Number of subjects: 0
Study 2104084 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, single subcutaneous injection)
Number of subjects: 0
Study 2104084 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 534419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin plus physostigmine
Number of subjects: 5
Study 534419 — intervention group
Group type: COMPARATOR
Intervention: Lecithin
Number of subjects: 5
Study 534419 — intervention group
Group type: COMPARATOR
Intervention: Physostigmine without lecithin
Number of subjects: 5
Study 31697802 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized-stage FL
Number of subjects: 666
Study 31697802 — intervention group
Group type: COMPARATOR
Intervention: Advanced-stage FL
Number of subjects: 666
Study 31097088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic vinorelbine (OMV) 50 mg three-times weekly
Number of subjects: 120
Study 31097088 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 120
Study 29759622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace-guided group (PG)
Number of subjects: 74
Study 29759622 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (PVI)
Number of subjects: 74
Study 25862833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (100 ppb)
Number of subjects: 26
Study 25862833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (200 ppb)
Number of subjects: 26
Study 23419077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 84
Study 23419077 — intervention group
Group type: COMPARATOR
Intervention: Acceptance and commitment therapy
Number of subjects: 84
Study 21254886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 603
Study 21254886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 603
Study 21254886 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 603
Study 21254886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 603
Study 19726290 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil preconditioning (5 microg/kg in 50 ml normal saline)
Number of subjects: 24
Study 19726290 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline only)
Number of subjects: 24
Study 16406153 — intervention group
Group type: COMPARATOR
Intervention: Memory activation during picture memory task
Number of subjects: 12
Study 16406153 — intervention group
Group type: COMPARATOR
Intervention: Memory activation during word memory task
Number of subjects: 12
Study 15771036 — intervention group
Group type: EXPERIMENTAL
Intervention: FastTrack rehabilitation program with epidural analgesia, short laparotomy, early feeding and mobilisation
Number of subjects: 40
Study 15771036 — intervention group
Group type: EXPERIMENTAL
Intervention: FastTrack rehabilitation program
Number of subjects: 40
Study 15771036 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative treatment with a pain control program
Number of subjects: 40
Study 11239652 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially expanding access device
Number of subjects: 34
Study 11239652 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting-tip trocar
Number of subjects: 34
Study 9929658 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cold (acute rhinitis)
Number of subjects: 36
Study 9929658 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline (to control mucus secretion)
Number of subjects: 36
Study 7520904 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg/day
Number of subjects: 513
Study 7520904 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 513
Study 7520904 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 10 mg/day
Number of subjects: 513
Study 7520904 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 16 mg/day
Number of subjects: 513
Study 7520904 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg/day
Number of subjects: 513
Study 7520904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 2737236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg daily for 14 days
Number of subjects: 36
Study 2737236 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Na 100 mg daily for 14 days
Number of subjects: 36
Study 1102233 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzquinamide, 100 mg 3 times daily
Number of subjects: 183
Study 1102233 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine, 10 mg 3 times daily
Number of subjects: 183
Study 1102233 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzquinamide
Number of subjects: 183
Study 31402006 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 (LNS for children aged 6-18 months)
Number of subjects: 3738
Study 31402006 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (LNS for pregnant or lactating women)
Number of subjects: 3738
Study 31402006 — intervention group
Group type: COMPARATOR
Intervention: T0 (standard-of-care programme)
Number of subjects: 3738
Study 28723831 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 2.5 mg
Number of subjects: 240
Study 28723831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 5.0 mg
Number of subjects: 240
Study 28723831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 7.5 mg
Number of subjects: 240
Study 28723831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 10.0 mg
Number of subjects: 240
Study 28723831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 7.5 mg or higher
Number of subjects: 240
Study 26627641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 247
Study 26627641 — intervention group
Group type: COMPARATOR
Intervention: gp100 peptide vaccine
Number of subjects: 247
Study 22744302 — intervention group
Group type: COMPARATOR
Intervention: HL-90%
Number of subjects: 43
Study 22744302 — intervention group
Group type: COMPARATOR
Intervention: Pmax - bw
Number of subjects: 43
Study 22744302 — intervention group
Group type: COMPARATOR
Intervention: Pmax + bw
Number of subjects: 43
Study 22744302 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 43
Study 21950130 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological tests aimed to elucidate situational and personal anxiety, aggressiveness and hostility.
Number of subjects: 0
Study 21950130 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of body mass index, activity of sympathetic nervous system, serum leptin level.
Number of subjects: 0
Study 19452100 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX + GCs (prednisone)
Number of subjects: 69
Study 19452100 — intervention group
Group type: COMPARATOR
Intervention: ETN + MTX
Number of subjects: 69
Study 16522653 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines-based intervention (early contact of absentees; addressing psychosocial obstacles; offering temporary modified work; communicating among the players)
Number of subjects: 2918
Study 16522653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2918
Study 14562564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antifibrinolytic therapy
Number of subjects: 0
Study 14562564 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11090726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with acute normovolemic hemodilution (ANH)
Number of subjects: 28
Study 11090726 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with acute hypervolemic hemodilution (HHD)
Number of subjects: 28
Study 11090726 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypotension with prostaglandin E1 (PGE1)
Number of subjects: 28
Study 9373242 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD34(+) marrow graft (Arm A)
Number of subjects: 89
Study 9373242 — intervention group
Group type: COMPARATOR
Intervention: Standard buffy coat fraction (Arm B)
Number of subjects: 89
Study 9373242 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD34(+) marrow graft (Arm A) with >/=1.2 x 10(6) CD34(+) cells/kg
Number of subjects: 89
Study 9373242 — intervention group
Group type: COMPARATOR
Intervention: Standard buffy coat fraction (Arm B) with >1.2 x 10(6) CD34(+) cells/kg
Number of subjects: 89
Study 1392429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 37
Study 1392429 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 37
Study 3965335 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5‐mm endoscope with diazepam
Number of subjects: 146
Study 3965335 — intervention group
Group type: COMPARATOR
Intervention: 8.5‐mm endoscope with no sedation
Number of subjects: 146
Study 3965335 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5‐mm endoscope with diazepam
Number of subjects: 146
Study 3965335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam sedation
Number of subjects: 146
Study 3965335 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller endoscope (8.5‐mm)
Number of subjects: 146
Study 3965335 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior history of cardiovascular disease
Number of subjects: 146
Study 31210421 — intervention group
Group type: EXPERIMENTAL
Intervention: RDP using the “3+2” mode
Number of subjects: 106
Study 31210421 — intervention group
Group type: COMPARATOR
Intervention: RDP using the classical mode
Number of subjects: 106
Study 29530088 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (60 mg/kg)
Number of subjects: 34
Study 29530088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27341346 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 632
Study 27341346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 632
Study 24804281 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous hard and soft tissue grafts
Number of subjects: 49
Study 22285755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 106
Study 22285755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Number of subjects: 106
Study 22285755 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 106
Study 20348359 — intervention group
Group type: EXPERIMENTAL
Intervention: Catholic‐tailored program
Number of subjects: 34
Study 20348359 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral program
Number of subjects: 34
Study 18550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at weeks 0, 2, 6, and 14 with MTX (10‐17.5 mg/week) and prednisolone (<10 mg/day)
Number of subjects: 5
Study 18550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 5
Study 11581553 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at a dose of 3.5 mg/kg body weight administered by deep intramuscular injection once a week for 12 weeks
Number of subjects: 10
Study 11581553 — intervention group
Group type: COMPARATOR
Intervention: Saline-based placebo (nonTE)
Number of subjects: 10
Study 9692843 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPE regimen
Number of subjects: 27
Study 9692843 — intervention group
Group type: COMPARATOR
Intervention: EC regimen
Number of subjects: 27
Study 9692843 — intervention group
Group type: EXPERIMENTAL
Intervention: DexaBEAM regimen
Number of subjects: 27
Study 9692843 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOEP regimen
Number of subjects: 27
Study 9692843 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI/IFOS regimen
Number of subjects: 27
Study 8025393 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling with a fat content of 35-45 E% of total energy intake (7-12 months) and 30-35 E% after 12 months, with a fatty acid ratio of 1:1:1
Number of subjects: 45
Study 8025393 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific dietary advice
Number of subjects: 45
Study 2901743 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 45
Study 2901743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 45
Study 2901743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2901743 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol and Cimetidine
Number of subjects: 45
Study 2901743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric juice somatostatin concentration
Number of subjects: 45
Study 31786177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition counseling once per month for 3 months
Number of subjects: 120
Study 31786177 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same educational resource at baseline without any discussion
Number of subjects: 120
Study 30396708 — intervention group
Group type: EXPERIMENTAL
Intervention: iTero
Number of subjects: 10
Study 30396708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava
Number of subjects: 10
Study 30396708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec infiniDent
Number of subjects: 10
Study 30396708 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow
Number of subjects: 10
Study 28808847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (20 mg, slow intravenous injection)
Number of subjects: 50
Study 28808847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study 26259134 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2) per day with GnRHa
Number of subjects: 107
Study 26259134 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2) per day with GnRHa
Number of subjects: 107
Study 26259134 — intervention group
Group type: COMPARATOR
Intervention: GH 1 mg/m(2) per day
Number of subjects: 107
Study 26259134 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2) per day
Number of subjects: 107
Study 23411653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual and religious beliefs and practices
Number of subjects: 132
Study 23411653 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 132
Study 23411653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 132
Study 23411653 — intervention group
Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 132
Study 22071701 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg daily)
Number of subjects: 285
Study 22071701 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg/kg daily)
Number of subjects: 285
Study 22071701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg daily)
Number of subjects: 285
Study 19164454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine ± platinum-based chemotherapy
Number of subjects: 1775
Study 16298507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine
Number of subjects: 0
Study 15550855 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine
Number of subjects: 511
Study 15550855 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 511
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 514
Study 10680804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: PMH/SMS involving at least two areas combined with absence of early CT signs
Number of subjects: 514
Study 10680804 — intervention group
Group type: EXPERIMENTAL
Intervention: PMH/SMS involving three areas
Number of subjects: 514